For the quarter ending 2025-09-30, ADIL had -$1,308,691 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss from operations | -1,793,651 | -4,187,357 |
| Equity-based compensation | 147,334 | 360,830 |
| Amortization of intangible assets | 141 | 282 |
| Inducement expense | - | 0 |
| Change in value of equity method investment | -76,920 | -261,820 |
| Prepaid research and development | - | 0 |
| Change in fair value contingent consideration | 0 | 150,000 |
| Prepaid expenses and other current assets | 243,896 | -144,592 |
| Accrued expenses | 94,613 | -137,547 |
| Accrued expenses, related party | - | 0 |
| Accounts payable | -114,834 | 420,988 |
| Accounts payable, related party | 0 | 48,272 |
| Net cash used in operating activities | -1,833,373 | -3,334,664 |
| Cash receipt from contingent consideration | 0 | -150,000 |
| Net cash provided by investing activities | 0 | 150,000 |
| Net proceeds from sale of common stock | 477,642 | 3,127,187 |
| Proceeds from warrant exercise, net of expenses | 47,040 | 2,221,932 |
| Net cash provided by financing activities | 524,682 | 5,349,119 |
| Net increase in cash and cash equivalents | -1,308,691 | 2,164,455 |
| Cash and cash equivalents at beginning of period | 3,750,525 | - |
| Cash and cash equivalents at end of period | 4,606,289 | - |
ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC. (ADIL)